The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High-Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089
Abstract
Purpose: In 1990, fluorouracil (FU) plus levamisole for 1 year became standard adjuvant treatment for patients with high-risk stages II and III colon cancer. Intergroup (INT) 0089 assessed the relative contributions of leucovorin and levamisole in such patients. Patients and Methods: From 1988 to 1992, 3,794 patients were randomly assigned. Experimental treatment consisted of one of three chemotherapy regimens: the low-dose leucovorin plus FU (Mayo Clinic; LDLV) regimen, the high-dose leucovorin plus FU (Roswell Park; HDLV) regimen, and the low-dose leucovorin plus levamisole plus FU (LDLV plus LEV) regimen, each administered for 30 to 32 weeks. The control arm was levamisole plus FU (LEV) for 1 year. Results: After a median follow-up of 10 years, of 3,561 eligible patients, 1,691 (47%) have died and 1,330 (37%) have experienced disease recurrence; 137 (10%) of those experiencing recurrence are still alive. A total of 481 patients (13%) died without evidence of recurrence, and 1,723 (48%) are alive and disease free. Although there were toxicity differences among the four arms, none was statistically superior in disease-free or overall survival. Conclusion: The 6- to 8-month regimens of LDLV and HDLV without levamisole used in this trial, rather than the previous standard regimen of 12 months of LEV, have become widely used. INT-0089 has long-term follow-up of the largest clinical trial of patients with high-risk colon cancer, documenting not only the durability of the treatment effects, but also the natural history of patients with high-risk colon cancer, and analyses of treatment based on age, race, and comorbid conditions such as obesity, diabetes, and second primary cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002083220602 · Cited by 2,256
Self-citationLe Voyer, T. E., Sigurdson, E. R., Hanlon, A. L., Mayer, R. J., Macdonald, J. S., Catalano, P. J., & Haller, D. G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.062 · Cited by 1,149
Self-citationEfficacy of adjuvant fluorouracil and folinic acid in colon cancer
(1995) · The Lancet · doi:10.1016/s0140-6736(95)90696-7 · Cited by 1,066
Gill, S., Loprinzi, C. L., Sargent, D. J., Thomé, S. D., Alberts, S. R., Haller, D. G., Benedetti, J., Francini, G., Shepherd, L. E., Francois Seitz, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.059 · Cited by 1,021
Self-citationA Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients
Sargent, D. J., Goldberg, R. M., Jacobson, S. D., Macdonald, J. S., Labianca, R., Haller, D. G., Shepherd, L. E., Seitz, J. F., & Francini, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010957 · Cited by 986
Self-citationMoertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-5-199503010-00001 · Cited by 925
Self-citationSargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6071 · Cited by 713
Laurie, J. A., Moertel, C. G., Fleming, T. R., Wieand, H. S., Leigh, J. E., Rubin, J., McCormack, G. W., Gerstner, J. B., Krook, J. E., & Malliard, J. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1447 · Cited by 700
The randomization and stratification of patients to clinical trials
Zelen, M. (1974) · Journal of Chronic Diseases · doi:10.1016/0021-9681(74)90015-0 · Cited by 613
Wolmark, N., Rockette, H., Mamounas, E., Jones, J., Wieand, S., Wickerham, D. L., Bear, H. D., Atkins, J. N., Dimitrov, N. V., Glass, A. G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3553 · Cited by 493
Age and Adjuvant Chemotherapy Use After Surgery for Stage III Colon Cancer
Schrag, D., Cramer, L. D., Bach, P. B., & Begg, C. B. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.11.850 · Cited by 481
Gunderson, L. L., Sargent, D. J., Tepper, J. E., Wolmark, N., O'Connell, M. J., Begovic, M., Allmer, C., Colangelo, L., Smalley, S. R., Haller, D. G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.173 · Cited by 436
Self-citationImpact of Diabetes Mellitus on Outcomes in Patients With Colon Cancer
Meyerhardt, J. A., Catalano, P. J., Haller, D. G., Mayer, R. J., Macdonald, J. S., Benson, A. B., & Fuchs, C. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.125 · Cited by 374
Self-citationExact Significance Testing to Establish Treatment Equivalence with Ordered Categorical Data
Mehta, C. R., Patel, N. R., & Tsiatis, A. A. (1984) · Biometrics · doi:10.2307/2530927 · Cited by 328
Buroker, T. R., O'Connell, M. J., Wieand, H. S., Krook, J. E., Gerstner, J. B., Mailliard, J. A., Schaefer, P. L., Levitt, R., Kardinal, C. G., & Gesme, D. H. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.14 · Cited by 311
Meyerhardt, J. A., Catalano, P. J., Haller, D. G., Mayer, R. J., Benson, A. B., Macdonald, J. S., & Fuchs, C. S. (2003) · Cancer · doi:10.1002/cncr.11544 · Cited by 306
Self-citationGreene, F. L., Stewart, A. K., & Norton, H. J. (2002) · Annals of Surgery · doi:10.1097/00000658-200210000-00003 · Cited by 230
Green, R. J., Metlay, J. P., Propert, K., Catalano, P. J., Macdonald, J. S., Mayer, R. J., & Haller, D. G. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-4-200202190-00005 · Cited by 161
Self-citationMcCollum, A. D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.15.1160 · Cited by 146
Meyerhardt, J. A., Catalano, P. J., Schrag, D., Ayanian, J. Z., Haller, D. G., Mayer, R. J., Macdonald, J. S., Benson, A. B., & Fuchs, C. S. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-8-200310210-00008 · Cited by 119
Self-citationNew Tumor-Node-Metastasis Staging Strategy for Node-Positive (stage III) Rectal Cancer: An Analysis
Greene, F. L., Stewart, A. K., & Norton, H. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.015 · Cited by 95
Cancer Prevention: Strong Science and Real Medicine
Lippman, S. M., & Levin, B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.071 · Cited by 34
Sargent, D. J., Wieand, S., Benedetti, J., Labianca, R., Haller, D. G., Shepherd, L. E., Seitz, J. F., Francini, G., de Gramont, A., & Goldberg, R. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3502 · Cited by 27
Self-citationAdjuvant Therapy of Colorectal Cancer: Why We Still Don't Know
Buyse, M. (1988) · JAMA · doi:10.1001/jama.1988.03720240033031 · Cited by 18
Cited by
Colorectal cancer statistics, 2023
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21772 · Cited by 3,733
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
“Note: The Roswell Park Memorial Institute (RPMI) method of 5-FU + LV therapy as adjuvant chemotherapy (drip infusion of l-LV 250 mg/m(2) administered for 2 h; intravenous infusion of 5-FU 500 mg/m(2) slowly administered within 3 min at 1 h after initiating l-LV administration; and once weekly administration for six co…”
MethodAdjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
QUASAR Collaborative Group (2007) · The Lancet · doi:10.1016/s0140-6736(07)61866-2 · Cited by 1,437
Duration of adjuvant chemotherapy for stage III colon cancer
Grothey, A., Sobrero, A. F., Shields, A. F., Yoshino, T., Paul, J., Taieb, J., Souglakos, J., Shi, Q., Kerr, R., Labianca, R., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713709 · Cited by 1,092
Kuebler, J. P., Wieand, H. S., O'Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., Petrelli, N. J., Findlay, M. P., Seay, T. E., Atkins, J. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2974 · Cited by 1,056
Metadata
- Authors
- Haller, D. G., Catalano, P. J., Macdonald, J. S., O'Rourke, M. A., Frontiera, M. S., Jackson, D. V., & Mayer, R. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-12-01
- Volume
- 23
- Issue
- 34
- Pages
- 8671-8678
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2155521795
- Cited by
- 391
- References
- 30
- FWCI
- 9.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.